Wildcat, I appreciate your investment blog.
I haven’t sold a share of HGEN. Obviously the stock and sector is out of favor due to vaccine news. The announcement to increase enrollment in their p3 trial was met with disappointment. The good news is the trial is expected to fill quickly and I feel strongly that the decision to increase enrollment derisks the outcome. Know that Operation Warp Speed personnel have seen unblinded data, do you think they decided to partner with a lost cause? The interim results are trending better than standard of care. Severe critical COVID patients have scant options, steroids and stuff that’s not helpful. As I mentioned previously, Operation Warp Speed will be very helpful for a small company like HGEN, once you have a regulatory package (BLA) suitable for the US, it’s much less difficult to file applications worldwide.
Great vaccine news hurts HGENs COVID upside, but by no means kills it. OWS is buying medications and stockpiling. Also recognize this drug has been in development for quite some time for the purpose of immunomodulation. Clearing the regulatory hurdles for COVID approval helps speed other indications.
An analyst just reiterated a buy with a price target of $34. I’m waiting this out. Just my humble (biased) opinion.
https://www.smarteranalyst.com/new-blurbs/h-c-wainwright-thinks-humanigens-stock-is-going-to-recover/